- Iptacopan in Patients With ANCA Associated Vasculitis — Active Not Recruiting • Phase II • NCT06388941.
- Review the linked registry entry for study design, population, endpoints, and operational status.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to standard of care (SOC) to induce and maintain remission in study participants with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), when used in combination with rituximab (RTX) induction. The trial will also assess the impact of iptacopan on disease relapses, evolution of renal function and proteinuria, GC side effects, patients' immune status, and QoL. Conditions: Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis Interventions: Iptacopan, Placebo, Rituximab Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 84…